GPCR Congress
9th & 10th June 2010
Wednesday 9th June 2010 to Thursday 10th June 2010
Montreux Palace, Switzerland, -
£650.00/person
Over two days, the event will attract over 100 senior-level decision makers working in GPCR’s from the UK, Europe and US. This prestigious event will provide a forum for practitioners and prominent innovators to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment, during a 2 day conference programme.
Day 1
MEDICINAL CHEMISTRY
Focus upon the optimization of all areas of GPCR drug design including structure, mechanism, SAR, protein and ligand structure based drug design and molecular and in silico modelling
GPCR MODULATION
Closer studies into various aspects of GPCR’s including allosteric modulations from both a chemistry and biological aspect, dimerisation and oligomerisation.
Day 2
GPCR SCREENING
Examining the implementation of GPCR screening methods, HTS, HCS as well as exploring the roles of cell and label free screening, assay technology as well as determining cost effective assay formats.
GPCR SIGNALLING & DISCOVERY GPCR PROGRASMMES
Latest approaches to other important aspects of GPCR’s - including the role of signaling and trafficking, functional selectivity, polypharmacology and drug discovery programmes.
|
 |
|
|
| Hear insights and views from our leading line up of industry experts: |
|
|
|
Ulrich Wendt, Director Structural Biology, Sanofi-Aventis
|
|
|
|
Graeme Milligan, Professor or Molecular Pharmacology; Joint Research Director, Faculy of Biomedical and Life Sciences, University of Glasgow
|
|
|
|
Kevin Pfleger, Research Associate Professor, Head of the Laboratory for Molecular Endocrinology - GPCRs, Western Australian Institute for Medical Research and Centre for Medical Researcg, University of Western Australia
|
|
|
|
Zara Sands, Computational Medicinal Chemist, UCB
|
|
|
|
Robert Lane, Post Docutoral Fellow, Faculty of Science, Leiden/Amsterdam Center for Drug Research, Medicinal Chemistry, Univeristy of Leiden
|
|
|
|
Mike Hanson, Associate Director Structural Biology, Receptos
|
|
|
|
Rafael Franco, Professor, Department of Biochemistry and Molecular Biology, University of Barcelona
|
|
|
|
Florian Müllershausen, Laboratory Head Developmental & Molecular Pathways, Novartis
|
|
|
|
Jonathon Mason, Head of Computational Chemistry, Heptares Therapeutics, UK & Chief Scientist, Medicinal Chemistry, Lundbeck Research, DK
|
|
|
|
Prof. Ross Bathgate, Leader Neuropeptides Division, Florey Neuroscience Institutes, University of Melbourne, Australia
|
|
|
|
Caterina Bissantz, Chemistry technologies and Innovation, F.Hoffman La Roche
|
|
|
|
Steve Garland, Group Leader Lead Generation GSK
|
|
|
|
Keith Wreggett, Target Biology, Bioscience, AstraZeneca
|
|
|
|
Danilo Guerini, Department of BioChemistry, Novartis
|
|
|
|
David Gloriam, Department of Medicinal Chemistry, Copenhagen University
|
|
|
|
Paola Casarosa, Lab head, Post Development R&D Bronchodilators, Boehringer-Ingelheim Pharma
|
|
|
|
Jean Mazella, Lab Head, Institut de Pharmacologie Moleculaire et Cellulaire CNRS, University of Nice-Sophia Antipolis, France
|
|
|
|
Wim Meutermans, VP Discovery, Alchemia
|
|
|
|
Mike Wood, Associate Director, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center
|
|
|
|
Chris van Koppen, Team Lead, Molecular Pharmacology, Merck Research Laboratories
|
|
|
|
|
|
|
|
|
Event Agenda
